Gilead’s $11.5B Bet: What Two Companies Saw in One Week
Gilead Sciences disclosed $11.5 billion in acquisition charges for three deals, notably Ouro Medicines and Tubulis, on May 7, 2026. In the same week UCB paid $2.2 billion for Candid Therapeutics, a company with an almost identical dual‑target autoimmune platform. Both firms are betting on drugs that treat hard‑to‑manage autoimmune disorders and an ovarian‑cancer indication that disproportionately affect women. The parallel, high‑value moves signal that institutional capital is validating the underlying science before pivotal Phase 3 data are released.
Gene Editing Has the Science Figured Out and Now Needs an Entire Stack of New Business Models, Reimbursement Mechanics, and...
Gene editing has moved from scientific proof‑of‑concept to commercial reality, highlighted by Vertex's CASGEVY therapy earning $43 million in Q1 2026 and treating over 500 patients at a $2.2 million list price. While the science is solid, the therapy’s multi‑step delivery—spanning screening, cell...
Are These 3 Facts About the Netherlands Coincidental? Or Do They Add up to an Ominous Picture of Tomorrow’s World?
Netherlands lawmakers are debating a bill that would broaden the legal definition of an embryo to include genetic material from two men, two women, a single donor, or even human‑animal hybrids. The proposal, championed by some to keep pace with...
To Home Birth or Not to Home Birth?
The author’s third essay in a Substack series weighs the evidence on home, hospital, and birth‑center deliveries, citing peer‑reviewed studies to outline the trade‑offs. Data show that home births have fewer medical interventions but higher rates of neonatal transfer, while...
Rebuilding Patient Trust when Medical Advice Is Resisted
Physician Fabrizia Faustinella recounts a walk‑in clinic encounter where a single mother, Isabela, demanded antibiotics for presumed a urinary tract infection despite negative tests. The physician provided education and alternative treatment, yet the patient left dissatisfied, sought care elsewhere, and...
Is Novo Nordisk Turning the Page on CagriSema?
Novo Nordisk says its launch timeline for the dual‑agonist CagriSema remains unchanged despite scrapping a single‑chamber delivery device. The Phase 3 trial showed a 23% average weight loss over 84 weeks, impressive but still below Lilly’s tirzepatide at 25.5%. Meanwhile, Novo...
Omega-3 Supplements May Increase Risk of Cognitive Decline, Scientists Warn
Recent clinical observations highlight nuanced effects of cardiovascular therapies and diet on atrial fibrillation and neurovascular health. A small randomized trial found that high‑dose telmisartan (80 mg) reduced AF recurrences compared with the standard 40 mg dose, despite similar blood‑pressure control. Real‑world...
Drug Development Funnel: What I Learnt Building One From Scratch
A new D3.js funnel visualizes drug‑development attrition, showing that the headline billions‑dollar cost reflects cumulative failures rather than a single success. The plot reveals that pre‑clinical spending (~$430 M per approved drug) rivals the cost of late‑stage trials, and that only...
TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial
TriSalus Life Sciences announced on May 4 that patient enrollment has begun for the PREDICTT trial, a prospective study of its Pressure‑Enabled Drug Delivery (PEDD) platform in liver tumors. The investigator‑led trial at MD Anderson Cancer Center will enroll about 20...
Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity
Autolus Therapeutics announced a strategic restructuring that will trim its workforce by about 13%, generating $15 million in annual cost savings starting in 2027. Despite the cuts, the company will double its manufacturing capacity in 2026 to support growing commercial and...
Here Is Why Ovid Therapeutics (OVID) Is One of the Best Fast Growing Penny Stocks
Ovid Therapeutics saw its price target raised by H.C. Wainwright to $4 from $2, reflecting confidence in its advancing pipeline. The company reported clean safety data for a 7 mg dose of its GABA‑aminotransferase inhibitor OV329, with no serious adverse events....
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones
Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, up sharply from $1.3 million a year earlier, largely due to $20 million in development milestones from its LX9851 partnership with Novo Nordisk. Net loss narrowed dramatically to $1.0 million from $25.3 million in Q1 2025, aided...
AtaiBeckley (ATAI) Reports Positive Phase 2a Results for Social Anxiety Treatment EMP-01
AtaiBeckley announced expanded Phase 2a results for EMP‑01, an oral R‑MDMA formulation targeting Social Anxiety Disorder. The study showed a 38% reduction in patient‑reported symptoms and a 32% drop in real‑world avoidance behaviors by Day 43, with 49% of participants classified as...
Women Physicians’ Health Is Paying the Price of Medicine
Dr. Jessie Mahoney, a pediatrician and physician‑wellness coach, recounts her own health crises—from pregnancy complications during residency to a life‑altering ICU injury—to illustrate a broader epidemic among women physicians. She cites data showing that over half of the 1,000+ women...
Glucose Nanoparticles Help CBD Cross the Blood-Brain Barrier
Researchers have engineered glucose‑coated polymer nanoparticles that dramatically improve cannabidiol (CBD) delivery across the blood‑brain barrier. The particles use a PEG‑PHB core to solubilize CBD and a surface glucose layer to hijack GLUT‑1 transport, while reactive‑oxygen‑species triggers release in inflamed...
Cipher Pharmaceuticals Q1 2026 Update – CPH.to
Cipher Pharmaceuticals delivered a stronger‑than‑expected first‑quarter 2026, posting $12.5 million in revenue, a 4 percent year‑over‑year rise, and an 82 percent gross margin—up six points from the prior year. Adjusted EBITDA jumped 25 percent to $7.7 million, pushing the adjusted EBITDA margin to 62 percent, well...
What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days
Between March 20 and April 21, 2026, venture capital poured $2.58 billion into ten healthcare and life‑sciences rounds, concentrating on companies that own scarce inputs rather than generic digital‑health apps. The biggest check was Earendil Labs' $787 million AI‑native biologics financing, followed...
Uber’s Personal Injury Lawsuits Split Doctors and Lawyers
Uber has launched a series of federal RICO lawsuits targeting personal‑injury law firms and medical providers it says are inflating lien‑based claims from rideshare accidents. The company also backs a California constitutional amendment that would cap plaintiff contingency fees and...
Sex-Affirming Care vs Gender-Affirming Care
Gender‑Affirming Care, promoted by the World Professional Association for Transgender Health, has proliferated without a robust evidence base, prompting growing clinician unease as detransition numbers rise. The article contrasts this model with a proposed Sex‑Affirming Care approach that grounds treatment...
How Corporate Medicine Is Eroding Truth and Patient Dignity
Ronald L. Lindsay, a retired pediatrician, contrasts his early experience in academic medicine—where open debate, error disclosure, and moral safety were routine—with the later reality of corporate‑run health systems that prioritize documentation, metrics, and institutional risk. He recounts a recent...
White House Plans to Fire FDA Chief Marty Makary, Sources Tell WSJ
According to the Wall Street Journal, the Trump administration has signed off on a plan to remove Dr. Marty Makary as FDA commissioner, though officials say the decision is not final. Makary’s tenure has been marked by clashes with the...
Generative Braces Move Into Metal: An Interview with LightForce’s James Lawton
On April 28, 2026 LightForce Orthodontics launched LightBracket Metal, a patient‑specific 3D‑printed metal bracket generated directly from an orthodontist’s digital treatment plan. The product expands the company’s generative braces platform from ceramic to metal, targeting the 65% of patients who...
Bridging the Health Equity Gap with Artificial Intelligence
Artificial intelligence is poised to transform health care, offering earlier disease detection and decision‑support tools that could extend specialist expertise to underserved clinics. However, the technology inherits the biases of U.S. health‑care data, which often under‑represents uninsured, undocumented and digitally...
Weekly Neuroscience Update
A wave of recent neuroscience studies uncovers new mechanisms and risk factors across a spectrum of disorders. MRI data link lower abdominal fat to slower brain atrophy and better cognition, while a single psilocybin dose appears to trigger lasting anatomical...
What’s Your Heart’s GPA?
The American Heart Association’s Life’s Essential 8 (LE8) provides a 0‑to‑100 composite score that aggregates four health‑behavior and four health‑factor metrics into a single cardiovascular health grade. The average U.S. adult scores 65, roughly a D+ on traditional grading scales,...
17-Alpha Estradiol - Another Top Anti-Aging Drug
The post details efforts to source 17α‑estradiol (alfatradiol) for anti‑aging and renal‑protective research, listing vendors and pricing—including Octagonchem’s $1,200 for 100 g and Shanghai Jizhi’s roughly $80 for 200 mg (≈¥568). It proposes a group‑buy workflow that starts with small‑scale sampling, purity...
Research Reports Link Between Higher Dietary Inflammatory Index and Prostate Enlargement
A Frontiers in Nutrition study found that higher scores on the Dietary Inflammatory Index are associated with a roughly 7% increase in benign prostatic hyperplasia (BPH) risk for each point rise. The analysis of NHANES data showed a clear dose‑response...
Evening Update: Hantavirus Outbreak - America’s Public Health System Is Cracking Under Pressure.
A sudden surge in hantavirus infections has hit twelve U.S. states, pushing case numbers up 45% in the past six months. Rural hospitals are scrambling for ICU beds as severe respiratory symptoms strain limited resources. The CDC responded with a...
Trump’s Psychedelic Executive Order Is the Beginning of the End of Prohibition
On April 18, President Trump signed an executive order to accelerate research, regulatory review, and patient access to psychedelic therapies for serious mental illness. The order does not legalize or de‑criminalize psychedelics but directs the FDA to issue priority vouchers...
![No Nurse Is Better than a Bad Nurse in Your Child’s Home [PODCAST]](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://kevinmd.com/wp-content/uploads/young_thumbnail.png)
No Nurse Is Better than a Bad Nurse in Your Child’s Home [PODCAST]
Patient advocate Ashley Youngdale recounts how her son with Mobius syndrome faced life‑threatening gaps in home‑care nursing. Severe staffing shortages left her family training unqualified nurses, leading to multiple near‑death incidents and a video‑recorded abuse case that resulted in a...
Nobel Prize-Winning Economist Alvin Roth on Organ Markets
Nobel laureate Alvin Roth argues in a Washington Post op‑ed that the United States should legalize payments for kidney donors. He cites roughly 130,000 new kidney‑failure cases each year, a $55 billion Medicare burden, and a waiting list of 90,000 patients...
The $1 Trillion Cardiovascular Reset
The blog highlights Eli Lilly's $1.3 billion acquisition of Verve Therapeutics, targeting a one‑shot PCSK9 gene‑editing therapy that could replace daily statins. It underscores the massive adherence problem—up to 75% of statin users stop within two years—and the untapped 1.4 billion‑person market for...
Health Insurers and Organizations Literally Bribe Pediatricians to Give Your Baby Vaccines
A recent blog post reveals that numerous health insurers and state programs are offering financial incentives—often $2,500 per child—to pediatricians who administer up to 25 vaccine doses by age 2½. The author cites 27 examples across California, New Jersey, North...
Saban Community Clinic Breaks Ground on Crenshaw Family Health Center, Expanding Access For Over 287,000 Low-Income People in One of...
Saban Community Clinic broke ground on the Crenshaw Family Health Center, a two‑story facility in South Los Angeles that will serve more than 287,000 low‑income residents. The center will deliver medical, dental, behavioral health and pharmacy services under one roof,...
“Where Do I Start?”: How Governments Can Prioritise AI Solutions for Health
Governments face mounting pressure to deliver health outcomes with shrinking budgets and rising demand. While AI is touted as a solution, ministries lack a clear roadmap to identify high‑impact projects. A new paper offers a practical framework that helps officials...
Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA
The FDA has extended the priority review of Eli Lilly's subcutaneous Leqembi by three months, delaying the agency's action date while requesting additional information. The once‑weekly injection is designed to replace the current infusion regimen for patients with early Alzheimer’s...
Not Just Arthritis: A Joint Effort to Change Arthritis Care in Canada
Arthritis Society Canada released its 2026 State of Arthritis Report Card, revealing that one in five Canadians—more than those with diabetes, heart disease, cancer, stroke and dementia combined—live with arthritis, and half are under 65, including 25,000 children. Despite a...
Has the Population's Liver Tolerance Changed Since 2020?
A recent analysis of NHS Hospital Episode Statistics reveals that toxic liver disease (ICD‑10 code K71) has surged 189% compared with the 2016‑2019 baseline, affecting every adult age group. The increase is concentrated in the unspecified (K71.9) and hepatitis‑NEC (K71.6)...
Bruno Vision Care Wins 2026 MedTech Breakthrough Award
Bruno Vision Care’s Deseyne® daily‑disposable contact lens, the first FDA‑cleared Extended Depth of Focus (EDOF) lens for presbyopia, won the 2026 MedTech Breakthrough Award for Best New Technology Solution – Ophthalmology. The lens uses a patented hyper‑refractive central zone and...
Smart Hospitals Market to Reach $363.9 Billion by 2032, DataM Intelligence Reports, Driven by AI Clinical Workflows and Connected Care
DataM Intelligence projects the global smart‑hospital market to expand from $58.2 billion in 2024 to $363.9 billion by 2032, a 26.2% compound annual growth rate. The surge is driven by AI‑enabled clinical workflows, connected patient rooms, and remote monitoring that move health...
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
WHOOP unveiled a suite of health‑focused upgrades, adding on‑demand video consultations with licensed clinicians and EHR syncing through HealthEx, slated for a U.S. launch this summer. The platform also introduced two AI tools—My Memory, which lets members edit personal context,...
Health Tech World Brings NHS Procurement Insider to Exclusive AI Event
Health Tech World’s in‑person event "Unlocking the Healthcare AI Opportunity" adds Hugo Dragonetti, procurement and systems manager at NHS London Procurement Partnership, as its fifth panelist. The conference, co‑hosted with Teesside University London, will dissect the current state of AI...
The AI Hype in Healthcare Needs Randomized Evidence
The article argues that the AI hype in healthcare must be grounded in randomized evidence. Venture capital is flooding AI decision‑support tools, yet most lack RCT validation. Two recent trials illustrate the gap: a 10,422‑patient UVA predictive‑analytics study found no...
Kanvas Biosciences Receives New Funding to Develop First-In-Category Microbiome Therapeutic for Improving Maternal, Newborn and Child Health
Kanvas Biosciences announced a new investment from the Gates Foundation to develop the world’s first fully synthetic microbiome therapeutic targeting maternal environmental enteric dysfunction (EED). The product will use a complex, multi‑strain consortium designed with AI‑driven discovery and spatial microbiome...
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
STAAR Low‑Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology have launched the LGSOC Resource Guide on World Ovarian Cancer Day. The guide aggregates trusted educational content, videos, and FAQs to help patients, caregivers, and advocates navigate diagnosis,...
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment...
Vistagen announced that the final participant has finished the randomized, double‑blind portion of its Phase 3 PALISADE‑4 trial evaluating fasedienol nasal spray for acute social anxiety disorder. The company expects to release topline efficacy and safety data in the second quarter...
Etripamil
Etripamil (Cardamyst®) received FDA approval as a rapid‑acting, intranasal L‑type calcium channel blocker for converting acute paroxysmal supraventricular tachycardia (PSVT) episodes to sinus rhythm in adults. The drug leverages an ester‑sensitive phenylalkylamine scaffold to achieve fast onset and a short...
ChatGPT Adds Mental Health Safety Feature
OpenAI is introducing Trusted Contact, an optional safety feature that lets adult ChatGPT users nominate a single trusted person to be alerted if the AI detects serious self‑harm language. The system first notifies the user, then a trained human reviewer...
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences (NASDAQ: PLSE) announced it will present at the Bank of America Securities 2026 Healthcare Conference in Las Vegas on May 13. The company will showcase its proprietary nPulse™ nanosecond pulsed field ablation (nsPFA™) platform, which aims to treat...
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (Deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
Bristol Myers Squibb announced that the European Commission has approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis, either as monotherapy or with methotrexate. The approval follows positive Phase 3 POETYK PsA‑1 and POETYK PsA‑2 trials, which demonstrated statistically significant improvements in ACR20...